Literature DB >> 29526257

Bevacizumab in breast cancer: a targeted therapy still in search of a target population.

Douglas K Marks1, Kevin Kalinsky2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29526257     DOI: 10.1053/j.seminoncol.2017.10.011

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  1 in total

1.  VEGF-A165b levels are reduced in breast cancer patients at primary diagnosis but increase after completion of cancer treatment.

Authors:  Maria Margarete Karsten; Maximilian Heinz Beck; Angela Rademacher; Julia Knabl; Jens-Uwe Blohmer; Julia Jückstock; Julia Caroline Radosa; Paul Jank; Brigitte Rack; Wolfgang Janni
Journal:  Sci Rep       Date:  2020-02-27       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.